Mark E. Dmytruk - Oct 5, 2022 Form 4/A - Amendment Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Oct 5, 2022
Transactions value $
-$907,579
Form type
4/A - Amendment
Date filed
11/7/2022, 08:50 PM
Date Of Original Report
Oct 7, 2022
Previous filing
Oct 4, 2022
Next filing
Nov 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +618K +6792.38% 627K Oct 5, 2022 Direct F1
transaction DNA Class A Common Stock Sale -$908K -279K -44.51% $3.25 348K Oct 6, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -618K -24.56% 1.9M Oct 5, 2022 Class A Common Stock Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
F2 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
F3 On March 14, 2022, the Reporting Person filed a Form 4 that reported RSUs on a consolidated basis with holdings of Class B Common Stock. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports. In addition to the RSUs reported herein, the Reporting Person beneficially owns 658,133 shares of Class B Common Stock, which includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer This Form 4 amends and restates the Form 4 filed by the Reporting Person on October 7, 2022 to correct an error in Table II.